tiprankstipranks
Pliant Therapeutics (DE:9PT)
FRANKFURT:9PT
Germany Market
9PT
Pliant Therapeutics
RESEARCH TOOLSreports

Pliant Therapeutics (9PT) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

9PT Analyst Ratings

Hold
5Ratings
Hold
1 Buy
4 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Pliant
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9PT Stock 12 Month Forecast

Average Price Target

€2.34
▲(118.51% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is €2.34 with a high forecast of €2.63 and a low forecast of €1.75. The average price target represents a 118.51% change from the last price of €1.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.63027997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.3380266400000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75351998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.0884830746153846,1.2169661492307693,1.345449223846154,1.4739322984615386,1.6024153730769233,1.7308984476923077,1.8593815223076924,1.987864596923077,2.1163476715384615,2.2448307461538466,2.373313820769231,2.5017968953846155,{"y":2.63027997,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.0660020492307691,1.1720040984615385,1.2780061476923077,1.384008196923077,1.4900102461538463,1.5960122953846154,1.7020143446153848,1.808016393846154,1.9140184430769231,2.0200204923076925,2.126022541538462,2.232024590769231,{"y":2.3380266400000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.0210399984615384,1.082079996923077,1.1431199953846154,1.2041599938461538,1.2651999923076924,1.3262399907692308,1.3872799892307692,1.4483199876923076,1.5093599861538463,1.5703999846153847,1.6314399830769233,1.6924799815384617,{"y":1.75351998,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.002,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.057,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€2.63Average Price Target€2.34Lowest Price Target€1.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on DE:9PT
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
―
Hold
―
Reiterated
05/12/26
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
Piper Sandler Analyst forecast on DE:9PT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€2.63
Buy
145.82%
Upside
Reiterated
05/12/26
Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)
Canaccord Genuity Analyst forecast on DE:9PT
Edward Nash
Canaccord Genuity
Canaccord Genuity
€2.63
Hold
145.82%
Upside
Reiterated
05/12/26
Analyst Reiterates Hold on Pliant Therapeutics, Keeps 12-Month Price Target Unchanged at $3 Amid Early-Stage Risk-Reward Balance
Needham Analyst forecast on DE:9PT
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (NASDAQ: SIBN), Pliant Therapeutics (NASDAQ: PLRX) and Steris (NYSE: STE)
RBC Capital Analyst forecast on DE:9PT
Brian Abrahams
RBC Capital
RBC Capital
€1.75
Hold
63.88%
Upside
Reiterated
05/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ligand Pharma (NASDAQ: LGND), Pliant Therapeutics (NASDAQ: PLRX) and Oculis Holding (NASDAQ: OCS)
J.P. Morgan Analyst forecast on DE:9PT
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
12/04/25
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX), uniQure (NASDAQ: QURE) and Medtronic (NYSE: MDT)
Citi Analyst forecast on DE:9PT
Eric Joseph
Citi
Citi
―
Sell
―
Downgraded
10/10/25
Pliant Therapeutics downgraded to Underweight from Neutral at JPMorganPliant Therapeutics downgraded to Underweight from Neutral at JPMorgan
Jefferies Analyst forecast on DE:9PT
Faisal Khurshid
Jefferies
Jefferies
€1.75
Hold
63.88%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Pliant Therapeutics (NASDAQ: PLRX) and InflaRx (NASDAQ: IFRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on DE:9PT
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
―
Hold
―
Reiterated
05/12/26
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
Piper Sandler Analyst forecast on DE:9PT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€2.63
Buy
145.82%
Upside
Reiterated
05/12/26
Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)
Canaccord Genuity Analyst forecast on DE:9PT
Edward Nash
Canaccord Genuity
Canaccord Genuity
€2.63
Hold
145.82%
Upside
Reiterated
05/12/26
Analyst Reiterates Hold on Pliant Therapeutics, Keeps 12-Month Price Target Unchanged at $3 Amid Early-Stage Risk-Reward Balance
Needham Analyst forecast on DE:9PT
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (NASDAQ: SIBN), Pliant Therapeutics (NASDAQ: PLRX) and Steris (NYSE: STE)
RBC Capital Analyst forecast on DE:9PT
Brian Abrahams
RBC Capital
RBC Capital
€1.75
Hold
63.88%
Upside
Reiterated
05/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ligand Pharma (NASDAQ: LGND), Pliant Therapeutics (NASDAQ: PLRX) and Oculis Holding (NASDAQ: OCS)
J.P. Morgan Analyst forecast on DE:9PT
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
12/04/25
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX), uniQure (NASDAQ: QURE) and Medtronic (NYSE: MDT)
Citi Analyst forecast on DE:9PT
Eric Joseph
Citi
Citi
―
Sell
―
Downgraded
10/10/25
Pliant Therapeutics downgraded to Underweight from Neutral at JPMorganPliant Therapeutics downgraded to Underweight from Neutral at JPMorgan
Jefferies Analyst forecast on DE:9PT
Faisal Khurshid
Jefferies
Jefferies
€1.75
Hold
63.88%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Pliant Therapeutics (NASDAQ: PLRX) and InflaRx (NASDAQ: IFRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pliant Therapeutics

3 Months
Eric JosephCiti
Success Rate
4/6 ratings generated profit
67%
Average Return
+9.82%
Copying Eric Joseph's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.82% per trade.
1 Year
Eric JosephCiti
Success Rate
2/6 ratings generated profit
33%
Average Return
-18.45%
Copying Eric Joseph's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -18.45% per trade.
2 Years
Eric JosephCiti
Success Rate
1/6 ratings generated profit
17%
Average Return
-51.90%
Copying Eric Joseph's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -51.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9PT Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
2
3
1
1
Buy
0
0
0
0
0
Hold
4
4
7
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
10
5
5
In the current month, 9PT has received 1 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 9PT average Analyst price target in the past 3 months is 2.34.
Each month's total comprises the sum of three months' worth of ratings.

9PT Financial Forecast

9PT Earnings Forecast

Next quarter’s earnings estimate for 9PT is -€0.30 with a range of -€0.32 to -€0.28. The previous quarter’s EPS was -€0.28. 9PT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 9PT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9PT is -€0.30 with a range of -€0.32 to -€0.28. The previous quarter’s EPS was -€0.28. 9PT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 9PT has Performed in-line its overall industry.

9PT Sales Forecast

Next quarter’s sales forecast for 9PT is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9PT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 9PT has Performed in-line its overall industry.
Next quarter’s sales forecast for 9PT is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9PT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 9PT has Performed in-line its overall industry.

9PT Stock Forecast FAQ

What is DE:9PT’s average 12-month price target, according to analysts?
Based on analyst ratings, Pliant Therapeutics’s 12-month average price target is 2.34.
    What is DE:9PT’s upside potential, based on the analysts’ average price target?
    Pliant Therapeutics has 118.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pliant Therapeutics a Buy, Sell or Hold?
          Pliant Therapeutics has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Pliant Therapeutics’s share price target?
            The average share price target for Pliant Therapeutics is 2.34. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €2.63 ,and the lowest forecast is €1.75. The average share price target represents 118.51% Increase from the current price of €1.07.
              What do analysts say about Pliant Therapeutics?
              Pliant Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Pliant Therapeutics?
                To buy shares of DE:9PT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.